Close

Gilead Sciences (GILD) Announces Momelotinib Phase 3 Met Primary Endpoint in Myelofibrosis; Secondary Endpoint Missed

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. NFLX
2. TSM
3. ISRG
4. SPY
5. INFY
6. SNV
7. TSLA
8. SMCI
9. SLB
10. PPG


Go back to Gilead Sciences (GILD) Announces Momelotinib Phase 3 Met Primary Endpoint in Myelofibrosis; Secondary Endpoint Missed

Gabelli & Company Highlights 6 Potential Gilead Sciences (GILD) Takeover Targets

November 18, 2016 11:27 AM EST

Following Gilead Sciences' (NASDAQ: GILD) setback with its JAK 1/2 inhibitor momelotinib in myelofibrosis, Gabelli & Company analyst Jing He said she anticipates the company could be interested in buying someone else in oncology or rare disease.

In oncology, the analyst highlighted:

Incyte (NASDAQ:... More